Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [31] Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
    Menzella, Francesco
    Ballarin, Andrea
    Sartor, Maria
    Floriani, Ariel Fabian
    Corsi, Lorenzo
    Dartora, Cristina
    Tonin, Silvia
    Romagnoli, Micaela
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (11)
  • [32] The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies
    Lamberti, Mary Jo
    Kubick, Wayne
    Awatin, Josephine
    McCormick, John
    Carroll, James
    Getz, Ken
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (06) : 778 - 783
  • [33] The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies
    Mary Jo Lamberti
    Wayne Kubick
    Josephine Awatin
    John McCormick
    James Carroll
    Ken Getz
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 778 - 783
  • [34] Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review
    Khambholja, Kapil
    Gehani, Manish
    VALUE IN HEALTH, 2023, 26 (03) : 427 - 434
  • [35] Data Science Methods for Real-World Evidence Generation in Real-World Data
    Liu, Fang
    ANNUAL REVIEW OF BIOMEDICAL DATA SCIENCE, 2024, 7 : 201 - 224
  • [36] Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone, Daniel C.
    Brown, Mary
    Hurwitz, Jason T.
    Peters, Loretta
    Graff, Jennifer S.
    VALUE IN HEALTH, 2018, 21 (03) : 326 - 333
  • [37] Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform
    Bourla, Ariel B.
    Meropol, Neal J.
    DIGITAL HEALTH, 2021, 7
  • [38] Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making
    Sola-Morales, Oriol
    Siguroardottir, Katla
    Akehurst, Ron
    Murphy, Linda A.
    Mestre-Ferrandiz, Jorge
    Cunningham, David
    de Pouvourville, Gerard
    VALUE IN HEALTH, 2023, 26 (04) : 32 - 42
  • [39] Organic generation of real-world real-time data for clinical evidence in radiation oncology
    Bertolet, A.
    Wals, A.
    Miras, H.
    Macias, J.
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2020, 144
  • [40] Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making
    Franklin, Jessica M.
    Glynn, Robert J.
    Martin, David
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) : 867 - 877